Our findings suggest that SQAP is a potentially powerful tool to enhance the efficacy of RIT with lower toxicity, and TF-targeted RIT with SQAP is a promising therapeutic option for pancreatic cancer, even those that have metastasized. This evidence concerns the gene TF and familial pancreatic carcinoma.